COMMUNIQUÉS West-GlobeNewswire

RECORDATI ANNOUNCES STRATEGIC COLLABORATION WITH MODERNA TO DEVELOP AND COMMERCIALIZE WORLDWIDE mRNA 3927 FOR THE TREATMENT OF PROPIONIC ACIDEMIA
29/01/2026
mRNA-3927 is a strong strategic fit with Recordati’s rare Metabolic portfolio Collaboration combines Moderna’s expertise in mRNA technology for rare metabolic disorders with Recordati’s established global rare disease [...]
Option Care Health to Participate in the TD Cowen Healthcare Conference
29/01/2026
BANNOCKBURN, Ill., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Option Care Health, Inc. (“Option Care Health”) (Nasdaq: OPCH), the nation’s largest independent provider of home and alternate site infusion services, will [...]
Clover Health to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
29/01/2026
WILMINGTON, Del., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”), today announced that it will release its financial results after the [...]
Focus ADHD Expands Online Psychiatric Services to Adults Across Iowa
29/01/2026
DES MOINES, Iowa, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Focus ADHD, a premier online psychiatric clinic specializing in adult ADHD treatment, today announced the expansion of its telehealth services to patients throughout [...]
XTL Update on Recent Developments
29/01/2026
RAMAT GAN, ISRAEL, Jan. 29, 2026 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd. (Nasdaq:XTLB) (TASE:XTLB.TA) (the “ Company ” or “ XTL ”), announced that it is working diligently to close the acquisition of 85% of the [...]
Altimmune Announces Closing of $75 Million Registered Direct Offering of Common Stock
29/01/2026
GAITHERSBURG, Md., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, announced the closing of its [...]
BioSyent Declares First Quarter 2026 Dividend
29/01/2026
MISSISSAUGA, Ontario, Jan. 29, 2026 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its Board of Directors has declared a quarterly dividend of $0.055 per [...]
Park Dental Partners Announces Date for 2026 Annual Shareholders Meeting
29/01/2026
MINNEAPOLIS, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Park Dental Partners, Inc. (NASDAQ: PARK), a leading dental resource organization, today announced that it will hold its annual shareholder meeting on Friday, May 29, 2026 [...]
CVRx to Report Fourth Quarter 2025 Financial and Operating Results and Host Conference Call on February 12, 2026
29/01/2026
MINNEAPOLIS, Jan. 29, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions [...]
Picard Medical / SynCardia to Present Webinar on the Emperor Fully Implantable Total Artificial Heart Hosted by DeviceTalks
29/01/2026
TUCSON, Ariz., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (“Picard” or the “Company”), parent company of SynCardia Systems LLC, maker of the world’s first total artificial heart approved [...]
CareMed Has Been Selected as a National Specialty Pharmacy Provider for Exdensur (depemokimab-ulaa)
29/01/2026
NEW HYDE PARK, N.Y., Jan. 29, 2026 (GLOBE NEWSWIRE) -- CareMed, an independent specialty pharmacy, has been selected as a pharmacy partner by GSK for Exdensur (depemokimab), indicated for the add-on maintenance [...]
Lexicon Announces Proposed Public Offering of Common Stock
29/01/2026
THE WOODLANDS, Texas, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) (“ Lexicon ”) today announced that it has commenced an underwritten public offering to offer and sell, subject to [...]
Denali Therapeutics Announces Data Presentations on Enzyme TransportVehicle™ Programs for Hunter Syndrome, Sanfilippo Syndrome Type A and Pompe Disease at Upcoming 2026 WORLDSymposium™
29/01/2026
Hunter syndrome (MPS II) presentations will include analysis from continued follow-up of Phase 1/2 data for tividenofusp alfa (DNL310), currently under FDA Priority Review Preliminary data from Phase 1/2 study of DNL126 [...]
Grant of Restricted Stock Units and Warrants to Employees in Genmab
29/01/2026
Company Announcement COPENHAGEN, Denmark; January 29, 2026 – Genmab A/S (Nasdaq: GMAB) announced today that the Board of Directors decided to grant 32,806 restricted stock units and 34,307 warrants to employees of the [...]
AB Science reçoit un avis d'autorisation pour un brevet américain couvrant le masitinib dans le traitement du cancer de la prostate métastatique hormono-resistant
29/01/2026
COMMUNIQUÉ DE PRESSE AB SCIENCE REÇOIT UN AVIS D'AUTORISATION POUR UN BREVET AMÉRICAIN COUVRANT LE MASITINIB DANS LE TRAITEMENT DU CANCER DE LA PROSTATE MÉTASTATIQUE HORMONO-RESISTANT CETTE DÉCISION FAVORABLE DE L’ [...]
Ardena completes divestment of its Södertälje drug substance site in Sweden to Nanologica
29/01/2026
Ghent, Belgium, 29th January 2026 – Ardena, a specialist CDMO and bioanalytical CRO enabling precision medicines and other complex therapies, today announced that it has completed the divestment of its drug substance ( [...]
AB Science receives notice of allowance for US patent covering masitinib in the treatment of metastatic castrate resistant prostate cancer
29/01/2026
PRESS RELEASE AB SCIENCE RECEIVES NOTICE OF ALLOWANCE FOR UNITED STATES PATENT COVERING MASITINIB IN THE TREATMENT OF METASTATIC CASTRATE RESISTANT PROSTATE CANCER THIS POSITIVE DECISION FROM THE USA PATENT OFFICE [...]
Tevogen to Align Long-Term Stock-Based Incentive Program With Company Milestones, Including Revenue
29/01/2026
WARREN, N.J., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN ), today announced that the current time- and individual performance-based long-term stock incentive [...]
JenaValve Appoints John Molyneux to Vice President of Operations
29/01/2026
IRVINE, Calif., Jan. 29, 2026 (GLOBE NEWSWIRE) -- JenaValve Technology, Inc., developer and manufacturer of the Trilogy™ Transcatheter Heart Valve (THV) System, today announced the appointment of John Molyneux to Vice [...]

Pages